nach oben

Erschienen in:

01.03.2008 | Original Article

Plant-derived EpCAM antigen induces protective anti-cancer response

verfasst von: Robert Brodzik, Sergei Spitsin, Max Golovkin, Katarzyna Bandurska, Carla Portocarrero, Monika Okulicz, Zenon Steplewski, Hilary Koprowski

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 3/2008

Einloggen, um Zugang zu erhalten

Abstract

Immunotherapy holds great promise for treatment of infectious and malignant diseases and might help to prevent the occurrence and recurrence of cancer. We produced a plant-derived tumor-associated colorectal cancer antigen EpCAM (pGA733) at high yields using two modern plant expression systems. The full antigenic domain of EpCAM was efficiently purified to confirm its antigenic and immunogenic properties as compared to those of the antigen expressed in the baculovirus system (bGA733). Recombinant plant-derived antigen induced a humoral immune response in BALB/c mice. Sera from those mice efficiently inhibited the growth of SW948 colorectal carcinoma cells xenografted in nude mice, as compared to the EpCAM-specific mAb CO17-1A. Our results support the feasibility of producing anti-cancer recombinant vaccines using plant expression systems.

Armstrong A, Eck SL (2003) EpCAM: a new therapeutic target for an old cancer antigen. Cancer Biol Ther 2:320–326PubMed

Boehm R (2007) Bioproduction of therapeutic proteins in the 21st century and the role of plants and plant cells as production platforms. Ann N Y Acad Sci 1102:121–134PubMedCrossRef

Brady LJ (2005) Antibody-mediated immunomodulation: a strategy to improve host responses against microbial antigens. Infect Immune 73:671–678CrossRef

Brodzik R, Bandurska K, Deka D, Golovkin M, Koprowski H (2005) Advances in alfalfa mosaic virus-mediated expression of anthrax antigen in planta. Biochem Biophys Res Commun 338(2):717–722PubMedCrossRef

Brodzik R, Glogowska M, Bandurska K et al (2006) Plant-derived anti-Lewis Y mAb exhibits biological activities for efficient immunotherapy against human cancer cells. Proc Natl Acad Sci USA 103:8804–8809PubMedCrossRef

Choudhury A, Mosolits S, Kokhaei P et al (2006) Clinical results of vaccine therapy for cancer: learning from history for improving the future. Adv Cancer Res 95:147–202PubMedCrossRef

Dalgleish AG, Whelan MA (2006) Cancer vaccines as a therapeutic modality: the long trek. Cancer Immunol Immunother 55:1025–1032PubMedCrossRef

Emens LA (2006) Roadmap to a better therapeutic tumor vaccine. Int Rev Immunol 25:415–443PubMedCrossRef

Fox JL (2006) Turning plants into protein factories. Nat Biotechnol 24:1191–1193PubMedCrossRef

10.

Gleba Y, Klimyuk V, Marillonnet S (2005) Magnifection—a new platform for expressing recombinant vaccines in plants. Vaccine 23:2042–2048PubMedCrossRef

11.

Gleba Y, Klimyuk V, Marillonnet S (2007) Viral vectors for the expression of proteins in plants. Curr Opin Biotechnol 18(2):134–141PubMedCrossRef

12.

Goldstein DA, Thomas JA (2004) Biopharmaceuticals derived from genetically modified plants. Q J Med 97:705–716

13.

Golovkin M, Spitsin S, Andrianov V et al (2007) Smallpox subunit vaccine produced in planta confers protection in mice. Proc Natl Acad Sci USA 104(16):6864–6869PubMedCrossRef

14.

Hodge JW, Greiner JW, Tsang KY et al (2006) Costimulatory molecules as adjuvants for immunotherapy. Front Biosci 11:788–803PubMedCrossRef

15.

Ko K, Steplewski Z, Glogowska M, Koprowski H (2005) Inhibition of tumor growth by plant-derived mAb. Proc Natl Acad Sci USA 19:7026–7030CrossRef

16.

Koprowski H (2005) Vaccines and sera through plant biotechnology. Vaccine 23:1757–1763PubMedCrossRef

17.

Ma JK-C, Chikwamba R, Sparrow P, Fischer R, Mahoney R, Twyman RM (2005) Plant-derived pharmaceuticals–the road forward. Trends in Plant Sci 10:580–585CrossRef

18.

Marillonnet S, Giritch A, Gils M, Kandzia R, Klimyuk V, Gleba Y (2004) In planta engineering of viral RNA replicons: efficient assembly by recombination of DNA modules delivered by Agrobacterium. Proc Natl Acad Sci USA 101:6852–6857PubMedCrossRef

19.

Mosolits S, Markovic K, Frodin JE, Virving L et al (2004) Vaccination with Ep-CAM protein or anti-idiotypic antibody induces Th1-biased response against MHC class I- and II-restricted Ep-CAM epitopes in colorectal carcinoma patients. Clin Cancer Res 10:5391–5402PubMedCrossRef

20.

Mosolits S, Nilsson B, Mellstedt H (2005) Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials. Expert Rev Vaccines 4:329–350PubMedCrossRef

21.

Nagorsen D, Thiel E (2006) Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer. Clin Cancer Res 12:3064–3069PubMedCrossRef

22.

Neidhart J, Allen KO, Barlow DL et al (2004) Immunization of colorectal cancer patients with recombinant baculovirus-derived KSA (Ep-CAM) formulated with monophosphoryl lipid A in liposomal emulsion, with and without granulocyte-macrophage colony-stimulating factor. Vaccine 22:773–780PubMedCrossRef

23.

Pogrebnyak N, Golovkin M, Andrianov V et al (2005) Severe acute respiratory syndrome (SARS) S protein production in plants: development of recombinant vaccine. Proc Natl Acad Sci USA 102:9062–9067PubMedCrossRef

24.

Staib L, Birebent B, Somasundaram R et al (2001) Immunogenicity of recombinant GA733–2E antigen (CO17–1A, EGP, KS1–4, KSA, Ep-CAM) in gastro-intestinal carcinoma patients. Int J Cancer 92:79–87PubMedCrossRef

25.

Szala S, Froehlich M, Scollon M et al (1990) Molecular cloning of cDNA for the carcinoma-associated antigen GA733–2. Proc Natl Acad Sci USA 87:3542–3546PubMedCrossRef

26.

Verch T, Hooper DC, Kiyatkin A, Steplewski Z, Koprowski H (2004) Immunization with a plant-produced colorectal cancer antigen. Cancer Immunol Immunother 53:92–99PubMedCrossRef

Titel: Plant-derived EpCAM antigen induces protective anti-cancer response
verfasst von: Robert Brodzik
Sergei Spitsin
Max Golovkin
Katarzyna Bandurska
Carla Portocarrero
Monika Okulicz
Zenon Steplewski
Hilary Koprowski
Publikationsdatum: 01.03.2008
Verlag: Springer-Verlag
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 3/2008
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-007-0366-4

Neu im Fachgebiet Onkologie

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Brustkrebs-Prävention wird neu gedacht

04.06.2024 ASCO 2024 Kongressbericht

Zurzeit untersuchen Forschende verschiedene neue Ansätze zur Prävention von Brustkrebs bei Personen mit hohem Risiko. Darunter Denosumab, die prophylaktische Bestrahlung der Brust – und Impfungen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2008

Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells

Improving alloreactive CTL immunotherapy for malignant gliomas using a simulation model of their interactive dynamics

Potential contribution of naïve immune effectors to oral tumor resistance: role in synergistic induction of VEGF, IL-6, and IL-8 secretion

The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays

Lung carcinomas do not induce T-cell apoptosis via the Fas/Fas ligand pathway but down-regulate CD3 epsilon expression